Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ultragenyx Pharmaceutical Inc. filings document a rare-disease biopharmaceutical business with approved medicines, investigational genetic-disease therapies, and a Nasdaq-listed common stock capital structure. Form 8-K reports include operating results, financial guidance, FDA communications, clinical-study data, and risk language tied to drug development, regulatory review, manufacturing, funding needs, competition, and commercialization.
Proxy materials describe annual-meeting matters, board and compensation governance, equity compensation, and stockholder voting. Recent current reports also record restructuring and cost disclosures, employment-related equity plans, and material updates for programs including UX111, UX016, DTX301, DTX401, and GTX-102.
RARE reported an insider sale filing under Form 144. The filing lists proposed sales of Performance Shares: 688 and Restricted Stock: 5,330, both dated 03/01/2024. It also records a sale by KARAH PARSCHAUER of 8,135 common shares on 03/02/2026 for $185,485.61.
Ultragenyx Pharmaceutical Inc. officer John Richard Pinion reported stock-based compensation activity and a related tax sale. On March 1, 2026, he acquired 11,137 shares of common stock at $0.00 per share through the conversion of previously granted performance stock units after certification of performance metrics.
On March 2, 2026, he sold 10,029 common shares in an open-market transaction at a weighted average price of $22.80 per share, in multiple trades between $22.54 and $23.11, to pay required tax withholdings tied to RSU vesting. Following these transactions, he directly owned 110,026 common shares, including 490 shares from the employee stock purchase plan and shares underlying RSUs subject to vesting conditions.
Ultragenyx Pharmaceutical EVP & Chief Commercial Officer Erik Harris reported both an equity award and a related share sale. On March 1, 2026, he acquired 11,643 shares of common stock at $0.00 per share from previously granted performance stock units that converted upon certification of performance metrics.
On March 2, 2026, he sold 10,539 shares of common stock at a weighted-average price of $22.80 per share to cover required tax withholdings tied to restricted stock unit vesting. After these transactions, he directly held 89,515 shares of common stock, plus additional RSUs subject to vesting conditions.
Ultragenyx Pharmaceutical President & CEO Emil Kakkis reported equity compensation activity and a related tax sale. On March 1, 2026, previously granted performance stock units converted into 71,177 shares of common stock upon certification of performance metrics. On March 2, 2026, he sold 54,404 shares of common stock at a weighted average price of $22.80 per share to cover required tax withholdings from RSU vesting. After these transactions, he directly owned 658,994 shares and indirectly held 2,158,985 shares through the Emil Kakkis and Jenny Soriano Living Trust.
Ultragenyx Pharmaceutical EVP and Chief Legal Officer Karah Herdman Parschauer reported both a stock grant and a related share sale. On March 1, 2026, she acquired 11,137 shares of common stock at no cost through conversion of previously granted performance stock units upon certification of performance metrics. On March 2, 2026, she sold 8,135 shares of common stock in an open-market transaction at a weighted average price of $22.80 per share, in multiple trades between $22.54 and $23.11, to cover required tax withholdings due to vesting of restricted stock units. After these transactions, she directly held 76,346 shares, including shares acquired under the company’s employee stock purchase plan and shares underlying unvested restricted stock units subject to vesting conditions.
Ultragenyx Pharmaceutical Inc. senior vice president and chief accounting officer Theodore Alan Huizenga reported two common stock transactions. He completed an open-market sale of 1,632 shares at a weighted average price of $22.80 per share, primarily to cover required tax withholdings from vesting restricted stock units (RSUs).
In a related move, he also disposed of 148 shares at $23.39 per share through share surrender to satisfy additional tax obligations tied to RSU vesting. Following these tax-related and open-market transactions, he directly owned a total of 50,302 shares of Ultragenyx common stock, which includes previously reported unvested RSUs subject to vesting conditions.
Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported a mix of stock awards and sales. On March 1, 2026, he acquired 6,143 shares of common stock at no cost when previously granted performance stock units converted after the performance metric was certified. On March 2–3, 2026, he sold a total of 10,044 shares in open-market transactions at prices around the low‑$20s per share, with some shares sold to cover required tax withholdings from restricted stock unit vesting. After these transactions, he directly owned 85,034 shares of Ultragenyx common stock.
Ultragenyx Pharmaceutical EVP and Chief Medical Officer Eric Crombez reported a mix of stock award and sale transactions. On March 1, 2026, he acquired 11,643 shares of common stock at $0.00 per share through a grant, as previously granted performance stock units converted upon certification of performance metrics. On March 2, 2026, he executed an open-market sale of 7,029 shares of common stock at a weighted average price of $22.80 per share, with actual prices ranging from $22.54 to $23.11. A footnote states these shares were sold to pay required tax withholdings related to the vesting of restricted stock units. Following these transactions, Crombez directly held 76,301 shares of Ultragenyx common stock, which includes shares acquired under the company’s employee stock purchase plan and shares underlying restricted stock units that remain subject to vesting conditions.
Ultragenyx Pharmaceutical executive Dennis Karl Huang reported equity compensation activity involving company common stock. On March 1, 2026, he acquired 11,137 shares at a stated price of $0.00 per share through a grant/award, when previously granted performance stock units converted upon certification of a performance metric.
On March 2, 2026, he disposed of 999 shares at $23.39 per share, surrendering them back to Ultragenyx to cover required tax withholdings tied to restricted stock unit vesting. After these transactions, he directly owned 124,729 common shares.
Howard Horn reported Form 144 sales of RARE securities. The filing lists proposed sales of 674 performance shares and 961 restricted shares dated 03/01/2026. The form also discloses recent open-market dispositions by Howard Horn on 12/10/2025, 01/02/2026, 02/02/2026, and 03/02/2026 with individual share counts and gross proceeds shown.